Forbion European Acquisition, a blank check company formed by Forbion targeting the life sciences industry in Europe, raised $110 million by offering 11 million units at $10. The company offered 1 million more units than anticipated. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. Anchor investors had indicated on 15% of units in the offering, and the company may raise an additional $20 million at the closing of an acquisition pursuant to forward purchase agreements with an affiliate of the sponsor.
The company is led by CEO and Director Jasper Bos, who joined Forbion Growth as a General Partner in May 2021, and CFO and Director Cyril Lesser, Senior Controller at Forbion. The company plans to leverage management's experience and target late-stage opportunities in the life sciences industry in Europe.
Forbion European Acquisition plans to list on the Nasdaq under the symbol FRBNU. UBS Investment Bank and Kempen acted as joint bookrunners on the deal.
